tirzepatide weight loss data as Compared with Semaglutide for the Treatment of Obesity Tirzepatide and Injectable Semaglutide Correlated

No referral is required to be seen at our Georgetown weight loss clinic

Tirzepatide commonly causes gastrointestinal side effects, particularly during dose escalation phases

( PMID: 31389984 ) Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BY (2014) International consensus on drug allergy

For patients with type 2 diabetes, prediabetes, or cardiovascular risk factors, GLP-1's dual metabolic and appetite benefits may align better with clinical goals

Further analyses are planned to address some of these variables

Delivery lead time may vary per location from the date of payment confirmation